All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0/M1A/M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
melanoma (ML), ipilimumab plus gp100 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
0.84 [0.55 ; 1.27 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 86% 1,079 low not evaluable DORdetailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.68 [0.55 ; 0.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 25 NA not evaluable objective responses (ORR)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 4.06 [0.94; 17.43]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
1.28 [0.16 ; 9.97 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 85% 1,079 low not evaluable AE (any grade)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.95 [0.54; 7.01]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
1.96 [0.79 ; 4.84 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.94 [0.63; 1.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
0.97 [0.73 ; 1.28 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable TRAE (any grade)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 2.17 [1.28; 3.67]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
2.08 [1.43 ; 3.03 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.64 [0.90; 2.99]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
1.36 [0.91 ; 2.04 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable TRAE leading to death (grade 5)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.36 [0.28; 6.47]
1.36 [0.28 ; 6.47 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 539 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.39 [0.15 ; 12.46 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Colitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 8.58 [0.50; 146.20]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
1.58 [0.12 ; 20.33 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 68% 1,023 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 5.01 [0.65; 38.48]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
1.59 [0.28 ; 9.13 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 61% 1,023 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 2.80 [0.15; 53.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
0.59 [0.07 ; 5.18 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 51% 1,023 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 8.05 [1.07; 60.32]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
2.03 [0.20 ; 20.30 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 79% 1,023 low not evaluable Hepatitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.69 [0.06 ; 7.66 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
0.71 [0.16 ; 3.24 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 12% 1,023 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
0.51 [0.10 ; 2.70 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.69 [0.06 ; 7.66 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Increase AST TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.17 [0.02; 1.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.27 [0.04 ; 1.95 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Increased ALT TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.39 [0.15 ; 12.46 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Pruritus TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.69 [0.06 ; 7.66 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Rash TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 3.51 [0.19; 64.62]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
2.22 [0.39 ; 12.59 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results MDX010 Ipi plus gp100 vs gp100, 2010 6.38 [0.37; 110.82]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.56 [0.33; 7.34]
2.15 [0.55 ; 8.37 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Vitiligo TRAE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.35 [0.01; 17.55]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.01; 17.42]
0.35 [0.02 ; 5.54 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Abdominal pain AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.29 [0.09; 0.87]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
0.47 [0.14 ; 1.62 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 40% 1,023 low not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.33 [0.14; 0.78]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.95 [0.30; 3.03]
0.52 [0.18 ; 1.45 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 52% 1,023 low not evaluable Constipation AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.04 [0.11; 10.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.07; 1.70]
0.49 [0.13 ; 1.84 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Cough AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
0.69 [0.06 ; 7.66 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Decreased appetite AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.51 [0.14; 1.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
0.67 [0.25 ; 1.84 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Diarrhoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 6.13 [0.81; 46.56]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.83 [0.34; 2.05]
1.82 [0.27 ; 12.37 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 68% 1,023 low not evaluable Dyspnoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.80 [0.30; 2.14]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.96 [0.34; 2.73]
0.87 [0.43 ; 1.78 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Fatigue AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 1.68 [0.56; 5.04]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.71 [0.31; 1.62]
1.01 [0.44 ; 2.31 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 34% 1,023 low not evaluable Headache AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.45 [0.10; 2.06]
0.46 [0.16 ; 1.33 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Nausea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.17; 2.80]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.68 [0.17; 2.78]
0.69 [0.26 ; 1.85 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Pyrexia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.34 [0.05; 2.47]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
0.51 [0.10 ; 2.71 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable Vomiting AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.81 [0.21; 3.17]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.20; 3.14]
0.80 [0.31 ; 2.11 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2 0% 1,023 low not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 14:50 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 549